Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

NCT02611778 is registered in ClinicalTrials.gov with Bioeq GmbH as lead sponsor.

NCT NCT02611778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02611778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Lead sponsor
Bioeq GmbH
Phase
Phase 3
Overall status
Completed
Start date
December 19, 2015
Completion date
June 6, 2018
Enrollment
712 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (amd)